Strange Bedfellows: Generics Firms Join Big Pharma In Opposing Price Negotiation Legislation
Executive Summary
Concerns that Medicare drug price negotiation provisions in the Build Back Better legislation would upend the generic and biosimilar industries might resonate with legislators more than complaints from branded drug companies.
You may also be interested in...
AAM CEO Leonard Departs After Two Years, Creating Another Trade Group Searching For New Leader
David Gaugh, AAM’s executive VP of sciences and regulatory affairs, was named the interim CEO, making him the fourth person to run the association since February 2020.
Amgen Mvasi, Kanjinti Sales Decline As Biosimilars Industry Faces New Policy Challenges
ASP metric used in Medicare, and often in commercial insurance, for reimbursement of physician-administered drugs is an important factor in the sales arc for biosimilars. Price negotiations under IRA could bring their own margin-squeezing pain to pharmacy-benefit biosimilars.
Medicare Part B Payment Boost For Biosimilars A Positive Step But ‘More Must Be Done’
The policy is welcomed by biosimilar stakeholders, but amounts to a relatively small increase. To qualify for the revised payment, a biosimilar must have an average sales price that is less than its reference drug’s ASP and not all do.